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Abstract
Background: Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson’s
disease. The purpose of the present study was to investigate the efficacy of amantadine in Parkinson’s disease patients
suffering from dyskinesias.
Methods: In this multi-center, double-blind, randomized, placebo-controlled, cross-over trial, 36 patients with Parkinson’s
disease and dyskinesias were randomized, and 62 interventions, which included amantadine (300 mg /day) or placebo
treatment for 27 days, were analyzed. At 15 days after washout, the treatments were crossed over. The primary outcome
measure was the changes in the Rush Dyskinesia Rating Scale (RDRS) during each treatment period. The secondary outcome
measures were changes in the Unified Parkinson’s Disease Rating Scale part IVa (UPDRS-IVa, dyskinesias), part IVb (motor
fluctuations), and part III (motor function).
Results: RDRS improved in 64% and 16% of patients treated with amantadine or placebo, respectively, with significant
differences between treatments. The adjusted odds-ratio for improvement by amantadine was 6.7 (95% confidence interval,
1.4 to 31.5). UPDRS-IVa was improved to a significantly greater degree in amantadine-treated patients [mean (SD) of 1.83
(1.56)] compared with placebo-treated patients [0.03 (1.51)]. However, there were no significant effects on UPDRS-IVb or III
scores.
Conclusions: Results from the present study demonstrated that amantadine exhibited efficacious effects against dyskinesias
in 60–70% of patients.
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Introduction
Parkinson’s disease is one of the most prevalent neurodegener-
ative disorders, with an increasing prevalence in the elderly [1].
Motor disturbances due to Parkinson’s disease can be relieved by
medications containing levodopa or dopaminergic agonists, and
the majority of patients are treated with these drugs over a long
period of time. Motor complications, such as dyskinesias and
motor fluctuations, are often observed in long-term treated
patients. Deep-brain stimulation of the subthalamus is an
efficacious treatment for dyskinesias and motor fluctuations;
however, this surgical procedure is invasive and indications are
limited [2]. Motor complications such as dyskinesias impair quality
of life and are difficult to control [3]; de-escalation of levodopa
reduces dyskinesias, but is often associated with worsened motor
symptoms.
Studies have suggested that dyskinesias are due to over-release
of dopamine [4], hypersensitivity of striatal dopamine receptors
[5], or both. Animal dyskinesia experimental models have revealed
that the NR2B subunit of the N-methyl-D-aspartate (NMDA)-type
glutamate receptor is redistributed from synaptic sites to extra-
synaptic sites in the striatum [6]. The altered discharge pattern of
striatal medium spiny neurons plays an important role in
dyskinesias [7], and depolarization of these neurons requires
glutamatergic inputs [8,9]. Although glutamatergic inputs via
AMPA/kainate receptors might be involved [9], synergic synaptic
transmission via dopamine D1 receptors and NMDA receptors
underlies the occurrence of dyskinesias [10].
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NMDA receptors [11] and is expected to ameliorate dyskinesias.
Although previous studies have demonstrated that amantadine
exhibits anti-dyskinetic effects [12,13,14,15,16,17], and the duration
of anti-dyskinetic effects is attenuated to within 8 months [15], the
withdrawal of amantadine worsens dyskinesias, even after amanta-
dine treatment for 1 year or longer [17]. However, the evidence for
anti-dyskinetic effects of amantadine is insufficient [18,19]. There-
fore, the purpose of this study was to clarify the efficacy of
amantadine inpatients with dyskinesias. In addition,clinical features
associated with the anti-dyskinetic effects were investigated.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. This clinical trial was designed and reported
according to recommendations of the Consolidated Standard of
Reporting Trials (CONSORT) statement [20].
Study design and organization
This trial was registered in the UMIN Clinical Trial Registry
(UMIN 000000780) on July 30, 2007 (https://center.umin.ac.jp/
cgi-open-bin/ctr/ctr.cgi).
This multi-center, placebo-controlled, double-blinded, random-
ized, cross-over trial was organized by a study group comprising 13
sites in 11 prefectures in Japan. Amantadine hydrochloride was
donated by Novartis Pharma Corporation, Tokyo, Japan. The
study was conducted by a coordination center at Utano National
Hospital and was approved by the Bioethics Committee of Utano
National Hospital, the Ethica of National Center for Neurological
and Psychiatric Disorders, Ehime University Hospital IRB, the
Ethics Committee of Miyagi National Hospital, the Ethics
Committee of Mie University Hospital, the Ethics Committee at
Sagamihara National Hospital, the Ethical Committee of Research
Institute for Brain and Blood Vessels Akita, the Ethical Review
Committee of National Defense Medical College, the Ethics
Committee of Nishitaga National Hospital, Bioethics Committee
of Jichi Medical University, the Ethics Committee of Saigata
National Hospital, and the Institutional Review Board of Kagawa
Prefectural Central Hospital. All subjects were informed of study
protocols and study relevance, and the subjects provided written
consent. Safetywasmonitoredwithattentionpaid toadverseeffects.
Patients and eligibility
Eligible subjects were 20–75 years old and were diagnosed with
Parkinson’s disease (according to steps 1 and 2 of the United
Kingdom Parkinson’s Disease Society Brain Bank Diagnostic
Criteria [21]), as well as dyskinesias of the limbs or trunk. Severity
of dyskinesias was not considered as an eligibility criterion. Subjects
were excluded due to the following: (1) treatment with amantadine
hydrochloride in the previous two weeks; (2) psychiatric symptoms,
such as auditory hallucinations or delusions (patients with a past
history of visual hallucination were included); (3) estimated
creatinine clearance ,75 ml/min/1.73 m
2, according to the
Cockcroft-Gault formulation; (4) significant liver damage; (5)
pregnancy or possible pregnancy; or (6) history of epilepsy. Patients,
who met the criteria and were examined between July 2007 and
August 2008, were considered for the study. The drug doses for
Parkinson’s disease were fixed throughout the study period.
Randomization and treatment interventions
Patients were judged eligible by neurologists at the participating
hospitals and were consented for enrollment; peripheral blood was
sampled at each hospital, and creatinine clearance was calculated at
the coordination center. Eligible participants were provided unique
subject identification numbers according to study criteria and were
assigned to Arm 1 or Arm 2 by a research technician (K.H.),
according to a computer-generated, randomization plan, which
included stratification by severity of dyskinesia (ADL-interfering or
not-interfering). Study medications were sent to each hospital from
the coordinating center, according to the schedule. A list of subject
identificationnumbersandcorrespondingtreatmentassignmentswas
restricted to K.H. and were concealed from other study personnel.
Arm 1 intervention consisted of an observation period (2–3
weeks), amantadine hydrochloride treatment period (27 days),
washout period (15 days), and placebo treatment period (27 days).
Arm 2 intervention consisted of an observation period, placebo
period, a washout period, and an amantadine treatment period
(Figure 1,top).Amantadine wasincreasedina step-by-stepmanner
(100 mg for 7 days, 200 mg for 7 days, and 300 mg for 7 days),
followed by a decreased treatment regimen (200 mg for 3 days and
100 mg for 3 days). Placebo was also administered in a similar
manner. The subjects were interviewed every 7th day, and adverse
effects were monitored. Trial drugs were not increased if the patients
did not desire the increase or if adverse effects were detected.
Patient evaluations
The primary outcome measure was changes in the Rush
Dyskinesia Rating Scale (RDRS) from pre-intervention time points.
RDRS (from 0 absent to 4 violent dyskinesia), the inter-rater, and
intra-rater reliability, which were robust [22], was used for objective
evaluation of dyskinesias at the beginning and end of each
intervention. Patients and the family members were instructed to
video record typical dyskinesias while walking, drinking from a cup,
putting on a coat, and buttoning clothing during the 3 days prior to
the study visits, and RDRS scores were recorded according to the
videotapes. Patients were defined as ‘‘responders’’ when the RDRS
reduction by amantadine treatment was greater than with placebo
treatment. ‘‘Non-responders’’ were defined when RDRS reduction
by amantadine was the same or less than with placebo, and the
prevalence of improvement in RDRS was compared between
amantadine and placebo interventions.
The secondary outcome measures were changes in the Unified
Parkinson’s Disease Rating Scale-III (UPDRS-III) for motor
functions (from 0 best to 116 worst), UPDRS-IVa for dyskinesia
(from 0 absent to 13 worst) and UPDRS-IVb for motor fluctuations
(from 0 best to 7 worst). UPDRS-III was administered in the ON
period in patients with motor fluctuations. UPDRS-I, II, and IV
were assessed based on interviews with patients, and UPDRS-III
was evaluated according to findings of study examinations.
The relationships between response to amantadine and clinical
features, including subject characteristics (age, sex, duration of
disease, and age of onset), amantadine dose, amantadine plasma
concentrations, and doses of anti-Parkinson’s drugs (levodopa,
dopamine agonists, and entacapone) were compared. Dopamine
agonist doses were calculated as the levodopa equivalent dose
(LDED) [23]. Plasma concentrations of amantadine were
determined as previously reported [24] and were measured at
3–6 h after administration of the morning amantadine dose.
Sample size
Based on previous reports, dyskinesia scores were estimated to
improve by 21.1 [(1.6) mean (SD)] points on the UPDRS-IVa
following amantadine hydrochloride treatment [14]. Sample sizes
were determined by power analysis comparing the two means and
were calculated as 30 (60 interventions) to achieve a power.80%
and an error of 0.05 in the cross-over test.
Amantadine for Dyskinesias in Parkinson’s Disease
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15298Figure 1. Study design and flow diagram. Top, cross-over scheme of patients randomly allocated to Arms 1 and 2. In Arm 1, amantadine was
increased from 100 mg to 300 mg every 7 days, and decreased every 3 days. At 15 days after washout, placebo was administered in a similar manner.
In Arm 2, placebo was increased every 7 days and decreased every 3 days, which was followed by a similar washout period and amantadine was then
administered in the same fashion. Bottom, flow diagram of patients in the study.
doi:10.1371/journal.pone.0015298.g001
Table 1. Characterization of study participants.
Arm 1 Arm 2
amantadine to placebo placebo to amantadine
Characteristics (n=18) (n=17)
Age, mean (SD), y 63.9 (7.6) 62.0 (7.0)
Male, No. (%) 6 (33.3) 4 (23.5)
Duration of PD, mean (SD), y 13.5 (4.5) 13.3 (9.1)
L-Dopa, mean (SD), mg/day 447 (139) 435 (171)
LDED of dopamine agonists, mean (SD), mg/day 176 (108) 151 (129)
UPDRS-III, mean (SD), points 16.7 (14.0) 22.4 (8.6)
UPDRS-IV, mean (SD), points 8.0 (3.6) 7.4 (3.1)
RDRS, median (interquartile range), points 2.0 (1.25) 2.0 (0.0)
doi:10.1371/journal.pone.0015298.t001
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Changes in RDRS scores were regarded as ordinal variables and
were categorized into two levels [improved (changes in RDRS,0),
and not-improved (changes in RDRS$0)]. Binominal generalized
estimating equations with unstructured correlation matrix were
adapted to fit a repeated measure logistic regression, incorporating
treatment effects (amantadineorplacebo),periodeffects (interaction
of order effect and carry-over effect), and sex as main effect factors,
as well as pre-treatment UPDRS-IVa scores as a covariate. The
prevalence of improved RDRS was compared between amantadine
and placebo treatments. The odds-ratio for improved RDRS
following treatments was calculated according to the generalized
estimating equation. RDRS score changes from baseline were
regarded as ordinal variables, and generalized estimating equations
with unstructured correlation matrix were adopted to fit repeated
measure ordinal logistic regression incorporating treatment effects
(amantadine or placebo) and period effects (interaction of order
effect and carry-over effect), with sex as the main effect factor and
pre-treatment RDRS scores as a covariate.
UPDRS score changes were regarded as scale variables. Data were
analyzed using a mixed linear model, with correlated residuals
assuming treatment effects, period effects, and sex as fixed-effects
factors, pre-treatment scores as covariance, and interventions (first or
second) as repeated-effects factors. The adjusted mean difference in
scores was compared between amantadine and placebo treatments,
and the direct treatment and period effects were statistically analyzed.
Clinical factors associated with a response to amantadine were
analyzed using multivariate logistic regression models (backward
step-wise model with a likelihood ratio test). All statistical analyses




Of the 39 patients identified as potential participants, three were
excluded due to low creatinine clearance. The remaining 36
patients were randomized, with 19 and 17 patients allocated to
Arms 1 and 2, respectively. In Arm 1, one patient withdrew
consent prior to intervention, and 18 received amantadine. During
amantadine treatment, one patient withdrew consent, and the
remaining 17 patients received placebo and completed the study.
In Arm 2, all participants received placebo, but two patients
Figure 2. Score changes in RDRS, UPDRS-IVa (dyskinesias), IVb (motor fluctuation), and III (motor disturbance) following
amantadine and placebo treatment. Following amantadine treatment, RDRS scores improved in 64% of participants (22 points in 27%, and
21 point in 37%), but remained unchanged in 37% of participants. RDRS scores improved in 16% of participants, but did not improve in 84%,
following placebo treatment (A). UPDRS-IVa scores significantly improved following amantadine treatment (B). In contrast, UPDRS-IVb and III scores
did not improve following treatment with amantadine or placebo (C, D). Data are plotted as scattered diagrams and bars represent means with
standard deviations of raw data.
doi:10.1371/journal.pone.0015298.g002
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discontinued the study due to adverse events (one exhibited
worsening dyskinesia, and one fell and experienced a fracture)
during the washout period. The remaining 13 participants
received amantadine and completed the study. Data from 30
amantadine interventions (17 in Arm 1, and 13 in Arm 2) and 32
placebo interventions (17 in Arm 1, and 15 in Arm 2), as well as 32
participants, were analyzed in a full analysis set (Figure 1). The
two treatment groups were similar at baseline with respect to
demographic and clinical variables (Table 1).
Efficacy measurements
Following amantadine treatment, RDRS scores improved in
64% of participants, and placebo treatment resulted in improve-
ment in 16% of participants (Figure 2A). Statistical analysis
utilizing generalized estimating equations revealed a statistically
significant difference in prevalence of improvement in RDRS
between amantadine and placebo treatments (P=0.016), although
the period effect was not statistically significant (P=0.31). The
odds-ratio of improvement by treatment was 6.7 [95% confidence
interval (CI), 1.4 to 31.5] following adjustment for period effects.
RDRS changes from baseline are shown in Table 2, with
significant differences between treatment (P=0.002, repeated
measure ordinal logistic regression model using generalized
estimating equations). (See Videos S1 and S2; typical patient
presenting dyskinesia.)
The unadjusted changes of UPDRS-IVa, IVb, and III from
baseline, as well as the adjusted differences between amantadine and
placebo interventions, are shown in Table 3.T h e r ew a sn op e r i o d
effect in score changes, and UPDRS-IVa scores improved by a mean
(SD) of 1.83 (1.56) following amantadine treatment and 0.03 (1.51)
following placebo treatment (Figure 2B). There was a statistically
significant treatment effect (P,0.001), and the adjusted difference
was a mean (95% confidence intervals) of 2.02 (1.22–2.83). UPDRS-
IVb and III scores remained unchanged following amantadine or
placebo treatment (Figure 2C, D) with no significant treatment
effect on changes (UPDRS-IVb: P=0.87, and UPDRS-III: P=0.26).
These results were identical when results from the first intervention
only were analyzed to avoid carry-over effects (Table S1).
Safety analysis
Adverse events were observed in nine patients (six receiving
amantadine, one receiving placebo, and two during washout). The
most common adverse effect was visual hallucinations, which was
observed in three patients during the amantadine treatment
period. The prevalence of adverse effects was significantly greater
in patients receiving amantadine treatment compared with
placebo treatment (P=0.048) (Table 4).
Clinical features associated with anti-dyskinetic effects
Of the 30 participants who completed the study, 20 patients
responded to amantadine. The demographical (age and sex) and
clinical features [onset age of Parkinson’s disease, dose of L-Dopa,
entacapone, and dopamine agonist (LEDD), dyskinesia severity
(pretreatment UPDRS-IVa) and plasma concentration of aman-
tadine] were included for analysis using multivariate logistic
regression models. Results showed that patients with a higher age
of Parkinson’s disease onset (odds-ratio=5.9 (95% confidence
interval, 1.1–32.6, P=0.04)/10 years) and higher doses of
dopamine agonists (odds-ratio=10.0 (1.2–81.3)/100mg LDED)
were more likely to respond to amantadine.
Discussion
The anti-dyskinetic effects of amantadine have been previously
evaluated in six studies (three parallel [12,15,17] and three cross-
over [13,14,16] studies). Although a cross-over design study has
the advantage that the sample size could be reduced, period
effects, including carry-over effect, cannot be neglected. In the
present study, the treatment effect was evaluated following
statistical adjustment for period effects and amantadine-improved
dyskinesias. Anti-dyskinetic effects were confirmed in both
Table 3. Score changes in amantadine and placebo interventions.
Unadjusted Adjusted difference*
Amantadine Placebo P Value
(n=30) (n=32) treatment effect period effect
change of UPDRS-IVa, mean (SEM) 21.83 (0.28) 0.03 (0.27) 22.02 (0.39) ,0.001 0.48
change of UPDRS-IVb, mean (SEM) 20.27 (0.18) 20.28 (0.16) 0.05 (0.28) 0.87 0.77
change of URDRS-III, mean (SEM) 21.23 (0.62) 21.43 (0.81) 1.85 (1.60) 0.26 0.23
*Difference of score changes (negative values indicate improvement) was adjusted for sex, period effect, pretreatment scores using a mixed linear model.
n: number of interventions.
doi:10.1371/journal.pone.0015298.t003
Table 2. RDRS score changes in amantadine and placebo treatment.
Treatment Change of RDRS Treatment effect
22p t 21p t 0p t +1 pt Adjusted OR (95% CI)* p
amantadine, n (%) 8 (26.7) 11 (36.7) 11 (36.7) 0 (0.0) 10.4 (2.0 to 47) 0.002
placebo, n (%) 1 (3.1) 4 (12.5) 23 (71.9) 4 (12.5)
*Odds ratio was adjusted for sex, period effect, pretreatment RDRS score, in an ordinary logistic regression model using general estimating equations.
n: number of interventions.
doi:10.1371/journal.pone.0015298.t002
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decreased by 1 or 2 points in 63.4% of patients following
amantadine treatment, and the changes reached a clinically
meaningful level, because RDRS is scored according to
interference with function of voluntary movement or daily
activities. The adjusted treatment effect in UPDRS-IVa was
estimated at 2.02, which was consistent with previous results
[12,13,14,15,16]. Though it is important to evaluate the quality-
of-life or cost-benefit ratios with amantadine therapy, these data
were not obtained because the original aim of this study was to
investigate the efficacy of anti-dyskinetic effects.
UPDRS-III (motor disturbance) was not altered by amantadine
treatment, which was consistent with previous studies
[13,14,16,17]. Motor disturbance effects have been shown to be
masked by a sufficient dose of L-dopa and dopamine agonists
during advanced stages of disease [13].
Results demonstrated that amantadine ameliorated dyskinesias
in 20 of 30 patients, but was not efficacious in the remaining 10
patients. Multivariate logistic analysis revealed that higher age-
of-onset and use of dopamine agonists positively associated with
the response to amantadine. Because dyskinesias are more often
observed and are more severe in young-onset PD patients
compared with elderly-onset patients [25], amantadine might
not suppress severe dyskinesias in younger patients. However,
the severity of dyskinesia was not identified as an associated
factor in the present study. Previous results have shown that
transient dyskinesia observed immediately following subthala-
motomy is not ameliorated by amantadine [26]. Therefore,
activity in the subthalamic nuclei could change with age and use
of dopamine agonists. However, further studies are needed to
determine the precise mechanisms underlying dyskinesias in
non-responders.
Conclusions
Results from the present study demonstrated that amantadine
was efficacious for dyskinesias in 60–70% of patients in advanced
stages of Parkinson’s disease.
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at Visit 2 (before the treatment). Dyskinesias in limbs and
trunk impaired activity of daily living are shown.
(MOV)
Video S2 Typical dyskinesias recorded from the same
patient at Visit 5 (amantadine, 300mg/d). Dyskinesias were
markedly improved. Videos S1 and S2 were recorded at exactly
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